Vasculonics
Vasculonics
  • Home
  • About
  • Science
  • NEWS
  • TEAM
  • Contact
  • More
    • Home
    • About
    • Science
    • NEWS
    • TEAM
    • Contact
  • Home
  • About
  • Science
  • NEWS
  • TEAM
  • Contact
data:image/gif;base64,R0lGODlhAQABAAD/ACwAAAAAAQABAAACADs=

Advance new class of disease modifying therapies for PAH and CKD patients

Advance new class of disease modifying therapies for PAH and CKD patientsAdvance new class of disease modifying therapies for PAH and CKD patientsAdvance new class of disease modifying therapies for PAH and CKD patients

Advance new class of disease modifying therapies for PAH and CKD patients

Advance new class of disease modifying therapies for PAH and CKD patientsAdvance new class of disease modifying therapies for PAH and CKD patientsAdvance new class of disease modifying therapies for PAH and CKD patients

About

Vasculonics is a preclinical stage biotechnology company focused on developing new class of disease modifying medicine for pulmonary artery hypertension (PAH) and chronic kidney disease (CKD).

We are focused on developing pharmacological approaches to reduce disease progression and mortality in PAH and CKD. 

Company Timeline

2017- Founded


2019- SBIR Phase I Award 

A Novel Therapeutic DDAH for the Treatment of Acute Kidney Injury


2020- SBIR Phase I Award 

Preclinical Development of a Novel Disease Modifying Therapy for Pulmonary Arterial Hypertension


2020- NHILB Catalyze Award

Synthesis New Compounds and Lead Optimization of Small Molecule DDAH-1 Modulator


2021- BARDA Blue Knight QuickFire Winner


2024- SBIR Phase II Award

Development of a Novel Disease Modifying Oral Therapy for Pulmonary Arterial Hypertension 


> $4 million grants awarded

Science and Technology

Selective Aryl Hydrocarbon Receptor Modulators (SAhRM)

AhR is known to play important pathological roles in inflammatory and fibrotic diseases [1,2]. AhR activation has been found essential for PAH progression in humans and animal models [3]. 


Vasculonics is developing novel selective aryl hydrocarbon receptor modulators (SAhRM) and suppressor of vascular toxin asymmetric dimethyl arginine (ADMA) the critical pathological mechanisms of PAH.  


VN-1032 is a novel SAhRM with major impact on the mechanisms of inflammation, oxidative stress and fibrosis.  


VN-1032 has demonstrated disease modifying efficacy in a PAH and CKD disease progression models when delivered as an oral formulation.


1. Beischlag TV., et al. Crit. Rev. Eukaryot. Gene Expr. 2008, 18 (3), 207–250.

2. Perdew GH., et al. Int. J. Mol. Sci. 2023, 24 (6).

3. Masaki T., et al. Proc. Natl. Acad. Sci. U. S. A. 2021, 118 (11), e2023899118.

VN-1032 reduced (A) kidney, (B) cardiac fibrosis in rat model of CKD. 

VN-1032 reduced (A) remodeling of lung vessels, (B) reduced lung inflammation in Sugen-Hypoxia PAH model.

Therapeutic Extracorporeal Device (TED)

Vasculonics has developed an extracorporeal device to selectively lower pathological ADMA from blood and demonstrate organ protection in preclinical models of kidney and heart damage [1]. Potential therapeutic applications of the extracorporeal device include the treatment of sepsis, acute kidney injury, and hepatic renal syndrome [2].


1. Lee Y., et al. Blood Purif. 2022, 51 (11), 889–898.

2. Singh J., et al. Critical Care. 2022, 26(1), 246.

News

Team Members

Jaipal Singh, PhD

CSO & Founder

Jon Northrup

CEO

Michael Coleman, PhD

CBO

Srinivas Kasibhatla, PhD

Chemistry Advisor

Young Lee, PhD

Program Leader

Advisory Board

Robert Bacallao, MD

Chief Medical Advisor

Vijay Reddy, PhD, DABT

SVP, Toxicology

Anantha Shekhar, MD, PhD

Co-Founder, SAB

John A Kellum, MD

SAB

Contact Us

Vasculonics

1800 North Capitol Avenue, Noyes Pavilion 5th Floor, E504C, Indianapolis, Indiana 46202, United States

Send Message

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cancel

Copyright © 2024 Vasculonics - All Rights Reserved.

  • FCOI Policy

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept